Frequency of cisplatin-induced severe renal injury in patients with solid tumours on renal scintigraphyMuhammad Inamullah, Mujahid Khalid Ali, Syed Mehdi Raza, Ehsan Mehmood, Zeeshan Ahmad Alvi.
Abstract Similar Articles
Objective: Cisplatin is an effective chemotherapeutic drug for the treatment of solid tumours. However, its nephrotoxic side effects limit its optimal use and renal scintigraphy may be a reliable diagnostic tool for detecting, evaluating, and quantifying any cisplatin-induced nephrotoxicity. This crosssectional retrospective study was designed to determine the frequency of cisplatin-induced severe renal injury by radionuclide renal scintigraphy in patients with solid tumours undergoing chemotherapy with cisplatin-based regimens. The at the Nuclear Medical Centre, Armed Forces Institute of Pathology (AFIP). Methods: 62 patients (48 male, 14 female) who were candidates for cisplatin-based chemotherapy and had normal renal function as evidenced by normal serum urea and creatinine levels and a normal value of ageadjusted GFR on 99mTc-99m-DTPA renal scintigraphy as per guidelines of National kidney Foundation, were subjected to post chemotherapy 99mTc-DTPA renal scintigraphy within 02 weeks of completion of 06 cycles cisplatin-based chemotherapy. Results: The frequency of severe renal injury was calculated as 2/62 (3.2%) as determined by 99mTc-DTPA scintigraphy after completion of 6 cycles of chemotherapy Conclusion: 3.2% of all patients developed severe renal injury at the completion of 6 cycles of cisplatin based chemotherapeutic regimen. This included patients with severe renal injury (GFR 15-29 ml/min) as well as patients with severe renal injury leading to absolute renal failure (GFR < 15 ml/min).